Annora Pharma
Last updated Jun 23, 2026
Evidence Sources
3
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
70%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Allergy
- Antihistamine
- Hematology
- Spleen Tyrosine Kinase Inhibitor
Highest priority development: FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
Regulatory precedent
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Annora Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 70%
Active Signals
2
Investigate Priority
0
Opportunity Score
43
Buyer Quality
7 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 23, 2026Score 22FDA Grants Approval for Fostamatinib Disodium ANDA217329
Hematology · Spleen Tyrosine Kinase Inhibitor
- MonitorJun 24, 2026Score 21FDA Grants Approval for Diphenhydramine Hydrochloride ANDA219470
Allergy · Antihistamine
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — MEPERIDINE HYDROCHLORIDE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Annora Pharma right now?
- Which regulatory precedents should Annora Pharma monitor in Allergy and Antihistamine?
- Which pipeline programs should Annora Pharma prioritize for competitive review?
- What signals require immediate investigation for Annora Pharma?
- Summarize the strategic implications of recent developments for Annora Pharma.
- Where is the greatest uncertainty in Annora Pharma's competitive positioning?